Gulhane Faculty of Medicine, University of Health Sciences, Ankara, Turkey.
Department of Bioengineering, Faculty of Engineering, Marmara University, Istanbul, Turkey.
OMICS. 2023 Jun;27(6):281-296. doi: 10.1089/omi.2023.0053. Epub 2023 Jun 1.
Plectin, encoded by , is a cytoskeletal and scaffold protein with a number of unique isoforms that act on various cellular functions such as cell adhesion, signal transduction, cancer cell invasion, and migration. While plectin has been shown to display high expression and mislocalization in tumor cells, our knowledge of the biological significance of plectin and its isoforms in tumorigenesis remain limited. In this study, we first performed pathway enrichment analysis to identify cancer hallmark proteins associated with plectin. Then, a pan-cancer analysis was performed using RNA-seq data collected from the Cancer Genome Atlas (TCGA) to detect the mRNA expression levels of and its transcript isoforms, and the prognostic as well as diagnostic significance of the transcript isoforms was evaluated considering cancer stages. We show here that several tissue specific isoforms are dysregulated in different cancer types and stages but not the expression of . Among them, and are potential biomarker candidates and call for further translational and personalized medicine research. This study makes a contribution as a stride to unravel the molecular mechanisms underpinning plectin isoforms in cancer development and progression by revealing the potent plectin isoforms in different stages of cancer as potential early cancer detection biomarkers. Importantly, uncovering how plectin isoforms guide malignancy and particular cancer types by comprehensive functional studies might open new avenues toward novel cancer therapeutics.
桥粒斑蛋白，由 编码，是一种细胞骨架和支架蛋白，具有许多独特的异构体，作用于各种细胞功能，如细胞黏附、信号转导、癌细胞侵袭和迁移。虽然已经表明桥粒斑蛋白在肿瘤细胞中显示出高表达和位置异常，但我们对桥粒斑蛋白及其异构体在肿瘤发生中的生物学意义的了解仍然有限。在这项研究中，我们首先进行了途径富集分析，以鉴定与桥粒斑蛋白相关的癌症标志性蛋白。然后，我们使用从癌症基因组图谱 (TCGA) 收集的 RNA-seq 数据进行了泛癌症分析，以检测 和其转录异构体的 mRNA 表达水平，并考虑癌症阶段评估转录异构体的预后和诊断意义。我们在这里表明，几种组织特异性 异构体在不同的癌症类型和阶段失调，但 表达不受影响。其中， 和 是潜在的生物标志物候选物，需要进一步进行转化和个性化医学研究。这项研究通过揭示不同癌症阶段的潜在桥粒斑蛋白异构体作为潜在的早期癌症检测生物标志物，为揭示桥粒斑蛋白异构体在癌症发展和进展中的分子机制做出了贡献。重要的是，通过全面的功能研究揭示桥粒斑蛋白异构体如何指导恶性肿瘤和特定癌症类型，可能为新型癌症治疗开辟新途径。
